Segmentation - CNS Specific Antisense Oligonucleotide Market

Antisense oligonucleotides are synthetic strings of nucleic acid, which reduce expression of messenger RNA (m-RNA). The function performed by interference with pre m- RNA splicing are restoration of protein and modification of protein. Antisense oligonucleotide is a new approach to treat several neurodegenerative disorders to prevent disease onset or stop disease development.

Market Dynamics

Increasing prevalence of neurodegenerative disease is a major factor driving CNS specific antisense oligonucleotide market growth. According to fact sheet from Alzheimer Association, an estimated around 5.7 million Americans were diagnosed with Alzheimer's dementia in 2018. Moreover, rich product pipeline for the treatment of CNS disorders and rare diseases associated with it is expected to boost the market growth. For instance, in December 2018, Biogen and Ionis Pharmaceuticals product IONIS-SOD1Rx (BIIB067) cleared Phase 1 clinical trial and is expected to be launched by 2020.

Key features of the study

This report provides in-depth analysis of the CNS specific antisense oligonucleotide market and provides market size (USD million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2018 – 2026), considering 2017, as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategy adopted by key players
It profiles key players in the global CNS specific antisense oligonucleotide market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include, Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Biogen Inc., Ionis Pharmaceuticals Inc., Wave Life Sciences Ltd., Stroke Therapeutic Inc., Dynacure, ProQR Therapeutics N.V., Q-STATE BIOSCIENCES, INC.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
The global CNS specific antisense oligonucleotide market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the CNS specific antisense oligonucleotide market

Market Segmentation